Literature DB >> 20798699

200 mg/m(2) melphalan--the gold standard for multiple myeloma.

Sergio Giralt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20798699     DOI： 10.1038/nrclinonc.2010.104

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol.

Authors:  Philippe Moreau; Cyrille Hullin; Frédéric Garban; Ibrahim Yakoub-Agha; Lotfi Benboubker; Michel Attal; Gérald Marit; Jean-Gabriel Fuzibet; Chantal Doyen; Laurent Voillat; Christian Berthou; Nicolas Ketterer; Philippe Casassus; Mathieu Monconduit; Mauricette Michallet; Albert Najman; Jean-Jacques Sotto; Régis Bataille; Jean-Luc Harousseau
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

2.  Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.

Authors:  Philippe Moreau; Thierry Facon; Michel Attal; Cyrille Hulin; Mauricette Michallet; Frédéric Maloisel; Jean-Jacques Sotto; François Guilhot; Gérald Marit; Chantal Doyen; Jérôme Jaubert; Jean-Gabriel Fuzibet; Sylvie François; Lotfi Benboubker; Matthieu Monconduit; Laurent Voillat; Margaret Macro; Christian Berthou; Véronique Dorvaux; Bernard Pignon; Bernard Rio; Thomas Matthes; Philippe Casassus; Denis Caillot; Norbert Najman; Bernard Grosbois; Régis Bataille; Jean-Luc Harousseau
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  The role of maintenance therapy in the treatment of multiple myeloma.

Authors:  Ashraf Z Badros
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

Review 4.  Importance of achieving a complete response in multiple myeloma, and the impact of novel agents.

Authors:  Asher A Chanan-Khan; Sergio Giralt
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

5.  Symptom burden in patients undergoing autologous stem-cell transplantation.

Authors:  K O Anderson; S A Giralt; T R Mendoza; J O Brown; J L Neumann; G M Mobley; X S Wang; C S Cleeland
Journal:  Bone Marrow Transplant       Date:  2007-04-16       Impact factor: 5.483

6.  Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma.

Authors:  Xin Shelley Wang; Sergio A Giralt; Tito R Mendoza; Martha C Engstrom; Beth A Johnson; Neomi Peterson; Lyle D Broemeling; Charles S Cleeland
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

7.  Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.

Authors:  Antonio Palumbo; Sara Bringhen; Benedetto Bruno; Antonietta Pia Falcone; Anna Marina Liberati; Mariella Grasso; Roberto Ria; Francesco Pisani; Clotilde Cangialosi; Tommaso Caravita; Anna Levi; Giovanna Meloni; Andrea Nozza; Patrizia Pregno; Attilio Gabbas; Vincenzo Callea; Manuela Rizzo; Luciana Annino; Valerio De Stefano; Pellegrino Musto; Ileana Baldi; Federica Cavallo; Maria Teresa Petrucci; Massimo Massaia; Mario Boccadoro
Journal:  Blood       Date:  2009-12-01       Impact factor: 22.113

8.  Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study.

Authors:  G L Phillips; B Meisenberg; D E Reece; V R Adams; A Badros; J Brunner; R Fenton; J Filicko; D Grosso; G A Hale; D S Howard; V P Johnson; A Kniska; K W Marshall; R Nath; E Reed; A P Rapoport; N Takebe; D H Vesole; J L Wagner; N Flomenberg
Journal:  Biol Blood Marrow Transplant       Date:  2004-07       Impact factor: 5.742
  8 in total
  4 in total

1.  DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.

Authors:  Maria Gkotzamanidou; Evangelos Terpos; Christina Bamia; Nikhil C Munshi; Meletios A Dimopoulos; Vassilis L Souliotis
Journal:  Blood       Date:  2016-07-21       Impact factor: 22.113

Review 2.  Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.

Authors:  M Martino; R M Lemoli; C Girmenia; L Castagna; B Bruno; F Cavallo; M Offidani; I Scortechini; M Montanari; G Milone; L Postacchini; A Olivieri
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

3.  Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

Authors:  M Gkotzamanidou; P P Sfikakis; S A Kyrtopoulos; C Bamia; M A Dimopoulos; V L Souliotis
Journal:  Br J Cancer       Date:  2014-07-22       Impact factor: 7.640

4.  Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.

Authors:  Holger W Auner; Simona Iacobelli; Giulia Sbianchi; Cora Knol-Bout; Didier Blaise; Nigel H Russell; Jane F Apperley; David Pohlreich; Paul V Browne; Guido Kobbe; Cecilia Isaksson; Stig Lenhoff; Christof Scheid; Cyrille Touzeau; Esa Jantunen; Achilles Anagnostopoulos; Ibrahim Yakoub-Agha; Alina Tanase; Nicolaas Schaap; Wieslaw Wiktor-Jedrzejczak; Marta Krejci; Stefan O Schönland; Curly Morris; Laurent Garderet; Nicolaus Kröger
Journal:  Haematologica       Date:  2017-12-07       Impact factor: 9.941
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.